Global Human Chorionic Gonadotropin (hCG) Market Size study & Forecast, by Technology (Natural Source Extraction, and Recombinant Technology), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermic Treatment), and End User (Fertil

Global Human Chorionic Gonadotropin (hCG) Market Size study & Forecast, by Technology (Natural Source Extraction, and Recombinant Technology), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermic Treatment), and End User (Fertility Clinics, Research Institutes) and Regional Analysis, 2022-2029

Global Human Chorionic Gonadotropin (hCG) Market is valued at approximately USD 0.92 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 7.6 % over the forecast period 2022-2029. During pregnancy, the placenta secretes a hormone called human chorionic gonadotropin (hCG). It signals the body to cease menstruating and thickens the uterine lining to support a developing embryo. After fertilisation, HCG levels increase and stay elevated for another 10 weeks or more of pregnancy. While treating infertility in women, hCG is used to maintain the luteal phase, promote final follicular maturation, and cause ovulation. It is used to increase testosterone production in males by the Leydig cells in conditions such as hormone insufficiency and male hypogonadism. The increasing incidence of male hypogonadism among the geriatric population and the growing popularity of hCG among healthcare professionals are key factors driving the market growth.

Over the years the prevalence of hypogonadism among male is contributing towards the growth of the Global Human Chorionic Gonadotropin (hCG) Market. For instance – as per Boston University Medical Campus (BUMC) estimates - Hypogonadism affects an estimated 4 to 5 million men in the United States. Also, growing healthcare infrastructure in developing economies as well as the rising availability of recombinant hCGs in different dose strengths would create lucrative growth opportunities for the market over the projected period. However, concern over cautions and warnings issued by the FDA over the probable side effects of hCG therapy hinders the market growth throughout the forecast period of 2022-2029. For instance, in July 2020, The Food and Drug Administration (FDA) announced an advisory for consumers to avoid HCG weight-loss products.

The key regions considered for the Global Human Chorionic Gonadotropin (hCG) Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the dominance of leading market players as well as the rise in the incidence of infertility-related problems both in males and females. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and increasing expansion of healthcare facilities in the region.

Major market player included in this report are:
Bristol Myers Squibb Company
Ferring Pharmaceuticals Inc
Merck & Co., Inc
Fresenius Kabi AG
Cigna
Sun Pharmaceutical Industries Ltd
Lee BioSolutions Inc
Sanzyme Biologics Private Ltd.
Scripps Laboratories Inc.
LUPIN Limited

Recent Developments in the Market:
 In july 2020, The FDA eliminated hCG, a weight-loss ingredient, from marketable products. The FDA continued by stating that all over-the-counter medications and diets that advertise the use of hCG as a weight-loss ingredient are false and illegal and that there is also no evidence to support the claims made. FDA continued by stating that the restriction of 500 calories per day while using the supplement has been introduced by the product sellers, which could be lethal.

Global Human Chorionic Gonadotropin (hCG) Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Technology, Therapeutic Area, End User, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Technology
Natural Source Extraction
Recombinant Technology
By Therapeutic Area
Female Infertility Treatment
Male Hypogonadism
Oligospermic Treatment
By End User
Fertility Clinics
Research Institutes

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Bristol Myers Squibb Company
Ferring Pharmaceuticals Inc
Merck & Co., Inc
Fresenius Kabi AG
Cigna
Sun Pharmaceutical Industries Ltd
Lee BioSolutions Inc
Sanzyme Biologics Private Ltd.
Scripps Laboratories Inc.
LUPIN Limited

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.